ROCHE XENICAL NDA WITHDRAWAL FITS PATTERN OF LABELING NEGOTIATIONS BETWEEN COMPANY AND FDA; DELAY WILL ALLOW MEDIA FUROR OVER OBESITY DRUGS TO ABATE
Executive Summary
Roche will conduct retrospective and epidemiological breast cancer analyses of its obesity therapy Xenical (orlistat) prior to resubmitting its NDA (20-766), the company said.